The developed HER2 targeted therapy primarily functions in four ways: 1) Directly binding with HER2 and inhibiting its dimerization, such as pertuzumab [39]; 2) Binding with HER2 and activating ADCC effects, such as trastuzumab [40]; 3) Targeting the intracellular catalytic kinase domain of HER2, such as Lapatinib [41]; 4) Binding with HER2 followed by internalization of the ADC and release of cytotoxic payload to kill tumor cells, such as Ado-trastuzumab emtansine (T-DM1), and T-Dxd [32]. Here, ERBB2 is linked to neoplasm.